Table 2.
Selected CAR T therapies in clinical trials. Data source ClinicalTrials.gov (www.clinicaltrials.gov, accessed on 25 June 2022).
| Disease Condition | Drug Combinations | Phase | Participants | Status | NCT Number |
|---|---|---|---|---|---|
| Breast cancer | 4SCAR T cells (CAR-T cells targeting Her2, GD2, and CD44v6) | I/II | 100 | Recruiting | NCT04430595 |
| Acute myeloid leukemia | CAR-T CD19 CD7 CAR-T cells |
II/III I/II |
10 108 |
Recruiting Recruiting |
NCT04257175 NCT04599556 |
| Multiple myeloma | CAR-T cell targeting B-cell maturation antigen (BCMA), Bortezomib, Dexamethasone, Lenalidomide, Cyclophosphamide, Fludarabine. JNJ-68284528 (cilta-cel), Pomalidomide, Bortezomib, Dexamethasone, Daratumumab JNJ-68284528 (ciltacabtagene autoleucel [cilta-cel], Bortezomib, Lenalidomide, Dexamethasone, Cyclophosphamide, Fludarabine, Daratumumab |
III III III |
650 419 750 |
Recruiting Active not yet recruiting Not yet recruiting |
NCT04923893 NCT04181827 NCT05257083 |
| B cell lymphoma | CAR-T-CD19, BTK inhibitor, Fludarabine, Cyclophosphamide | III | 24 | Recruiting | NCT05020392 |
| B Cell malignancies | CD19/CD22-CAR-T cells, fludarabine, cyclophosphamide | I/II | 146 | Not yet Recruiting | NCT05442515 |
| Solid tumor | CLDN6 CAR-T, CLDN6 RNA-LPX | I/II | 96 | Recruiting | NCT04503278 |
| Pancreatic cancer | CD276 CAR-T cells | I/II | 10 | Recruiting | NCT05143151 |
| Gastric cancer, Pancreatic cancer |
CT041 (CAR-T cells targeting claudin18.2) | I/II | 110 | Recruiting | NCT04404595 |
| Prostate cancer | 4SCAR-PSMA T cells [CAR-T cells targeting Prostate-specific membrane antigen (PSMA)] | I/II | 100 | Recruiting | NCT04429451 |
| CD44v6 positive cancers (squamous cell carcinomas, adenocarcinomas, melanoma, lymphoma) | 4SCAR-CD44v6 [CAR-T cells targeting CD44v6] | I/II | 100 | Recruiting | NCT04427449 |